Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Polyarticular Juvenile Idiopathic Arthritis Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550 (tofacitinib), placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Arthritis, Juvenile
Interventions
Golimumab, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
14
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Arthritis, Juvenile Idiopathic
Interventions
Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
4 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Hartford, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced May 21, 2026, 11:11 PM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
52
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Active Polyarticular Juvenile Idiopathic Arthritis
Interventions
Abatacept
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced May 21, 2026, 11:11 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, JIA
Interventions
adalimumab, Methotrexate
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Interventions
Certolizumab Pegol (CZP)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
10
States / cities
Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Hartford, Connecticut • Washington D.C., District of Columbia • Delray Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CNTO 148 (Golimumab), Placebo, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 18 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced May 21, 2026, 11:11 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced May 21, 2026, 11:11 PM EDT